BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3

• 

  Lung cancer

  Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again

  New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.

  September 3, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  Philips advances women’s health ultrasound with new single-transducer solution

  September 3, 2026

   · 

  4 min read
• Press Releases

  Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  September 3, 2026

   · 

  1 min read
• Press Releases

  Palisade Bio to Participate in Upcoming September 2026 Investor Conferences

  September 3, 2026

   · 

  2 min read
• Press Releases

  Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors

  September 3, 2026

   · 

  5 min read
• 

  Lung cancer

  RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

  The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall response rate and overall survival of 16 months.

  September 3, 2026

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Funding

  US to grant up to $125M for personalized RNA manufacturing innovation

  A new program from ARPA-H has devoted funding to make individualized RNA-based genetic medicine more efficient to produce and improve accessibility.

  September 3, 2026

   · 

  2 min read

   · 

  Michael Gibney
• 

  Layoffs

  TScan cuts 75% of workforce while shifting focus to solid tumor program

  TScan Therapeutics is looking for strategic partnerships for its heme and autoimmune programs while working to advance two in vivo T cell therapy candidates into investigational new drug–enabling studies.

  September 3, 2026

   · 

  2 min read

   · 

  Angela Gabriel
• Press Releases

  Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth

  September 3, 2026

   · 

  5 min read
• Press Releases

  BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

  September 3, 2026

   · 

  3 min read